naltrexone has been researched along with trk 820 in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (42.86) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 4 (19.05) | 2.80 |
| Authors | Studies |
|---|---|
| Iwata, S; Koyama, Y; Kutsumura, N; Miyata, Y; Nagase, H; Nagumo, Y; Nakajima, R; Saitoh, T; Yamamoto, N; Yoshida, N | 1 |
| Matsumiya, T; Nagase, H; Narita, M; Suzuki, T; Takeda, H; Tsuji, M | 1 |
| Endoh, T; Izumimoto, N; Kamei, J; Mizoguchi, H; Nagase, H; Narita, M; Saitoh, A; Suzuki, T; Tajima, A; Tseng, LF | 1 |
| Ando, N; Endoh, T; Honda, T; Kamei, J; Kawamura, K; Nagase, H; Okano, K; Tanaka, T; Togashi, Y; Umeuchi, H; Utsumi, J; Yoshizawa, Y | 1 |
| Hung, KC; Leitermann, R; Mizoguchi, H; Nagase, H; Narita, M; Suzuki, T; Tseng, LF | 1 |
| Honda, T; Nagase, H; Nakao, K; Okano, K; Tanaka, T; Togashi, Y; Umeuchi, H | 1 |
| Leitermann, RJ; Mizoguchi, H; Nagase, H; Narita, M; Suzuki, T; Tseng, LF | 1 |
| Aoki, CA; Gershwin, ME; Itoh, M; Kato, T; Kawashima, Y; Kikuchi, K; Kurokawa, T; Miyakawa, H; Nakao, K; Okano, K; Umeuchi, H | 1 |
| Hareyama, N; Ichinose, H; Ikeda, K; Kurokawa, T; Mochizuki, H; Nakajima, M; Nakao, K; Yoshikawa, S | 1 |
| Cowan, A; Dun, NJ; Inan, S | 2 |
| Fujii, H; Nagase, H | 1 |
| Kremer, AE; Mettang, T | 1 |
| Cowan, A; Inan, S; Kehner, GB | 1 |
| Abraham, AD; Andrews, MM; Baird, MA; Chavkin, C; Fontaine, HM; Kieffer, BL; Land, BB; Song, AJ | 1 |
| Kreek, MJ; Zhou, Y | 2 |
| Freeman, KB; Huskinson, SL; Naylor, JE; Prisinzano, TE; Townsend, EA; Zamarripa, CA | 1 |
| Townsend, EA | 1 |
| Cao, D; Gillespie, JC; Liu-Chen, LY; Mendez, RE; Selley, DE; Wang, H; Zhang, Y | 1 |
| Becker, C; Becker, G; Boehlke, C; Buroh, S; Coune, B; Hercz, D; Joos, L; Meerpohl, JJ; Schwarzer, G | 1 |
4 review(s) available for naltrexone and trk 820
| Article | Year |
|---|---|
Opioids in preclinical and clinical trials.
Topics: Amino Acid Sequence; Animals; Antitussive Agents; Clinical Trials as Topic; Drug Discovery; Humans; Molecular Sequence Data; Morphinans; Naltrexone; Receptors, Opioid, delta; Receptors, Opioid, kappa; Spiro Compounds; Structure-Activity Relationship | 2011 |
Uremic pruritus.
Topics: Acupuncture Therapy; Amines; Anti-Inflammatory Agents; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; gamma-Linolenic Acid; Humans; Morphinans; Naltrexone; Narcotic Antagonists; Pentoxifylline; Phototherapy; Pregabalin; Pruritus; Receptors, Opioid, kappa; Renal Insufficiency, Chronic; Spiro Compounds; Tacrolimus; Thalidomide; Uremia | 2015 |
Targeting Itch with Ligands Selective for κ Opioid Receptors.
Topics: Animals; Dynorphins; Guanidines; Humans; Ligands; Mice; Morphinans; Naltrexone; p-Methoxy-N-methylphenethylamine; Peptide Fragments; Pruritus; Receptors, Opioid, kappa; Spiro Compounds | 2015 |
Pharmacological interventions for pruritus in adult palliative care patients.
Topics: Animals; Capsaicin; Cromolyn Sodium; gamma-Aminobutyric Acid; Humans; Naltrexone; Ondansetron; Palliative Care; Paroxetine; Receptors, Opioid; Rifampin; Zinc Sulfate | 2023 |
17 other study(ies) available for naltrexone and trk 820
| Article | Year |
|---|---|
Antitrichomonal activity of δ opioid receptor antagonists, 7-benzylidenenaltrexone derivatives.
Topics: Animals; Antitrichomonal Agents; Benzylidene Compounds; CHO Cells; Cricetulus; Dose-Response Relationship, Drug; Molecular Structure; Naltrexone; Receptors, Opioid, delta; Structure-Activity Relationship; Trichomonas vaginalis | 2017 |
The novel kappa-opioid receptor agonist TRK-820 suppresses the rewarding and locomotor-enhancing effects of morphine in mice.
Topics: Animals; Dose-Response Relationship, Drug; Male; Mice; Morphinans; Morphine; Motor Activity; Naltrexone; Narcotics; Receptors, Opioid, kappa; Reward; Spiro Compounds | 2001 |
TRK-820, a selective kappa-opioid agonist, produces potent antinociception in cynomolgus monkeys.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Behavior, Animal; Macaca fascicularis; Morphinans; Morphine; Naloxone; Naltrexone; Pain Measurement; Pentazocine; Pentobarbital; Receptors, Opioid, kappa; Spiro Compounds | 2001 |
Antipruritic activity of the kappa-opioid receptor agonist, TRK-820.
Topics: Animals; Antipruritics; Chlorpheniramine; Disease Models, Animal; Histamine; Histamine H1 Antagonists; Ketotifen; Male; Mice; Mice, Inbred ICR; Morphinans; Motor Activity; Naltrexone; Pruritus; Receptors, Opioid, kappa; Spiro Compounds; Substance P | 2002 |
Blockade of mu-opioid receptor-mediated G-protein activation and antinociception by TRK-820 in mice.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics; Animals; Dose-Response Relationship, Drug; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; GTP-Binding Proteins; In Vitro Techniques; Injections, Intraventricular; Medulla Oblongata; Mice; Morphinans; Naltrexone; Narcotic Antagonists; Pain Measurement; Pons; Radioligand Assay; Receptors, Opioid, kappa; Receptors, Opioid, mu; Spiro Compounds | 2003 |
Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system.
Topics: Animals; Antipruritics; Behavior, Animal; Injections, Intraventricular; Injections, Subcutaneous; Ketotifen; Male; Mice; Morphinans; Morphine; Motor Activity; Naltrexone; Narcotic Antagonists; Pruritus; Receptors, Opioid, kappa; Receptors, Opioid, mu; Spiro Compounds; Substance P | 2003 |
Region-dependent G-protein activation by kappa-opioid receptor agonists in the mouse brain.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Benzeneacetamides; Brain; GTP-Binding Proteins; Guanosine 5'-O-(3-Thiotriphosphate); Male; Mice; Morphinans; Naltrexone; Narcotic Antagonists; Pyrrolidines; Receptors, Opioid, kappa; Spiro Compounds | 2004 |
Spontaneous scratching behavior in MRL/lpr mice, a possible model for pruritus in autoimmune diseases, and antipruritic activity of a novel kappa-opioid receptor agonist nalfurafine hydrochloride.
Topics: Age Factors; Animals; Antipruritics; Autoimmune Diseases; Behavior, Animal; Chlorpheniramine; Dermis; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Immunoglobulin E; Immunoglobulin G; Male; Mice; Mice, Inbred ICR; Mice, Inbred MRL lpr; Mice, Inbred Strains; Morphinans; Naltrexone; Pruritus; Receptors, Opioid, kappa; Sex Factors; Spiro Compounds | 2005 |
Effects of TRK-820, a selective kappa opioid receptor agonist, on rat schizophrenia models.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dopamine; Extracellular Space; Hyperkinesis; Male; Morphinans; Naltrexone; Phencyclidine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Schizophrenia; Serotonin; Spiro Compounds | 2009 |
Nalfurafine prevents 5'-guanidinonaltrindole- and compound 48/80-induced spinal c-fos expression and attenuates 5'-guanidinonaltrindole-elicited scratching behavior in mice.
Topics: Afferent Pathways; Analgesics, Opioid; Animals; Antipruritics; Biomarkers; Disease Models, Animal; Guanidines; Male; Mice; Morphinans; Naltrexone; Narcotic Antagonists; Nociceptors; p-Methoxy-N-methylphenethylamine; Pain Measurement; Posterior Horn Cells; Proto-Oncogene Proteins c-fos; Pruritus; Receptors, Opioid, kappa; Sensory Receptor Cells; Spinal Cord; Spiro Compounds; Treatment Outcome | 2009 |
Investigation of gastrin-releasing peptide as a mediator for 5'-guanidinonaltrindole-induced compulsive scratching in mice.
Topics: (4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride; Animals; Bombesin; Compulsive Behavior; Ganglia, Spinal; Gastrin-Releasing Peptide; Grooming; Guanidines; Locomotion; Male; Mice; Morphinans; Naltrexone; Nerve Fibers; Peptide Fragments; Pirenzepine; Pruritus; Receptor, Muscarinic M1; Receptors, Bombesin; Receptors, Opioid, kappa; Skin; Spinal Cord; Spiro Compounds | 2011 |
κ-Opioid Receptor Activation in Dopamine Neurons Disrupts Behavioral Inhibition.
Topics: Animals; Behavior, Animal; Compulsive Behavior; Disease Models, Animal; Dopaminergic Neurons; Dorsal Raphe Nucleus; Female; Inhibition, Psychological; Male; Mice; Mice, Inbred C57BL; Morphinans; Naltrexone; Narcotic Antagonists; Prefrontal Cortex; Receptors, Opioid, kappa; Reinforcement, Psychology; Spiro Compounds; Stress, Psychological; Ventral Tegmental Area | 2018 |
Combination of Clinically Utilized Kappa-Opioid Receptor Agonist Nalfurafine With Low-Dose Naltrexone Reduces Excessive Alcohol Drinking in Male and Female Mice.
Topics: Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Animals; Drug Evaluation, Preclinical; Drug Tolerance; Female; Male; Mice, Inbred C57BL; Morphinans; Naltrexone; Receptors, Opioid, kappa; Saccharin; Spiro Compounds; Sucrose | 2019 |
Clinically utilized kappa-opioid receptor agonist nalfurafine combined with low-dose naltrexone prevents alcohol relapse-like drinking in male and female mice.
Topics: Alcohol Drinking; Alcoholism; Analgesics, Opioid; Animals; Drinking; Ethanol; Female; Male; Mice; Mice, Inbred C57BL; Morphinans; Naltrexone; Narcotic Antagonists; Receptors, Opioid, kappa; Receptors, Opioid, mu; Recurrence; Secondary Prevention; Spiro Compounds | 2019 |
Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys.
Topics: Analgesics, Opioid; Animals; Behavior, Addictive; Cocaine; Diterpenes, Clerodane; Dose-Response Relationship, Drug; Macaca mulatta; Male; Morphinans; Naltrexone; Narcotic Antagonists; Oxycodone; Receptors, Opioid, kappa; Reinforcement, Psychology; Self Administration; Spiro Compounds | 2020 |
Effects of kappa opioid receptor agonists on fentanyl vs. food choice in male and female rats: contingent vs. non-contingent administration.
Topics: Analgesics, Opioid; Animals; Dose-Response Relationship, Drug; Female; Fentanyl; Male; Morphinans; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Reinforcement, Psychology; Spiro Compounds | 2021 |
Exploring the putative mechanism of allosteric modulations by mixed-action kappa/mu opioid receptor bitopic modulators.
Topics: Allosteric Regulation; Allosteric Site; Binding Sites; Humans; Ligands; Molecular Docking Simulation; Morphinans; Naltrexone; Protein Binding; Receptors, Opioid, kappa; Receptors, Opioid, mu; Spiro Compounds; Thermodynamics | 2021 |